Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02503982
Other study ID # 001-14-RMC
Secondary ID
Status Recruiting
Phase Phase 4
First received July 14, 2015
Last updated July 20, 2015
Start date December 2014
Est. completion date December 2016

Study information

Verified date June 2015
Source Rabin Medical Center
Contact Liat Ashkenazy-Hofnung, MD
Phone +972-54-4749345
Email LiatA3@clalit.org.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

Valganciclovir (VGC) is extensively used for cytomegalovirus (CMV) infection treatment and prophylaxis after solid organ transplantation (SOT). VGC dosing is problematic in children. VGC has variable absorption and is renally excreted. Area Under the Curve (AUC) (0-24) of 40-60 mcg∙h/L is a predictive pharmacokinetic parameter of efficacy and safety. Dosing based on manufacturer recommendations is supra-therapeutic in most cases. A few published dosing algorithms result in AUC out of range.

Objective: To prospectively validate a VGC administration dosing regimen and compare it to other dosing algorithms.

Methods: Children after SOT at Schneider Children's Medical Center, the largest tertiary pediatric center in Israel, were prospectively studied, starting Dec 2014. The dosing regimen was derived from Seattle Children's Hospital guidelines; 14-16 mg/kg/dose. For impaired renal function, stratified dose reduction was used. Blood was withdrawn at steady state: 2, 5 and 10 hours post dosing. Drug level was analyzed by high pressure liquid chromatography (HPLC).


Description:

Valganciclovir (VGC) is a novel drug used extensively as a prophylactic, preemptive and treatment agent for cytomegalovirus (CMV) infection after solid organ transplantation (SOT).

It is the valine ester prodrug of Ganciclovir (GCV), has a bioavailability of approximately 60%, which is up to 10-fold higher than oral GCV.

Based on the correlation between the Pharmacokinetic (PK) of VGC and its clinical efficacy found in adult studies, AUC (0-24) of approximately 40-60 mcg∙h/mL has been described as predictive PK parameter of efficacy. Considering the mechanism of action of VGC, relationships of exposure-efficacy and exposure-safety are expected to be similar in children and adults.

In 2009, a new dosing algorithm incorporating both body surface area (BSA) and renal function was introduced by the manufacturer for infants and young children:

Dose (mg) =7 × BSA × CrCl

Very few studies have evaluated this dosing for infants and young children. In 2010 the FDA published a safety alert confirming the excessively high dosage calculated by the dosing algorithm in children with low body weight, low body surface area, and normal serum creatinine. This type of patient was not routinely observed in the clinical trials used to derive and confirm the pediatric dose.

As the body weight decreases and/or as the Creatinine Clearance (CrCl) increases excessively high doses are calculated. There is unproportional variability of doses calculated by the algorithm for infants and young children with normal renal function.

Doses can reach as high as 4 fold higher than the weight-based common dosing.

Objective:

1. To prospectively validate a dosing regimen of VGC administration

2. and to compare it to other dosing algorithms.

Methods:

This is a prospective study of all pediatric SOT recipients who were treated with oral valganciclovir. The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function as shown in the table. Max dose was 900 mg.

Measurement of valganciclovir levels After three days of consistent oral dosing to ensure steady-state concentrations, drug levels were measured at 2, 5 and 10 h following administration of the dose, and were analyzed at the pharmacologic laboratory of "Asaf HaRofeh Medical Center" using standard HPLC, with a lower limit of detection of 0.5 mcg/mL and a coefficient of variation of <10%. AUCs were calculated using the trapezoidal method.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group N/A to 20 Years
Eligibility Inclusion Criteria:

1. children and adolescents 0-20 years old

2. Solid Organ Transplantation admitted after transplantation

3. Treatment with prophylactic Valganciclovir

Exclusion Criteria:

1. Treatment with ganciclovir IV

2. Glomerular Filtration Rate (GFR) < 25 mL/min/1.73 m2

3. Imipenem treatment

4. Cluster organ transplanted -

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Infection in Solid Organ Transplant Recipients

Intervention

Drug:
prophylactic Valganciclovir
The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.

Locations

Country Name City State
Israel Schneider childrens medical center of Isreal Petah Tikva

Sponsors (1)

Lead Sponsor Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve (AUC) Valganciclovir 24 hours No
See also
  Status Clinical Trial Phase
Completed NCT02260596 - Respiratory Viral Infections in Pediatric Transplantation N/A
Completed NCT01761435 - Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination Phase 3
Completed NCT04637321 - The Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
Completed NCT02382211 - T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays
Terminated NCT01761201 - "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Phase 3
Recruiting NCT05626530 - Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients Phase 4
Active, not recruiting NCT01527591 - Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT) N/A
Completed NCT01446445 - Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Phase 4
Completed NCT01833416 - Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients N/A
Completed NCT01558037 - Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients N/A